Aurobindo Pharma
Aurobindo Pharma Limited, commonly known as Aurobindo Pharma, is a prominent player in the global pharmaceutical industry, headquartered in Hyderabad, India. Founded in 1986, the company has established a strong presence in over 150 countries, with significant operations across North America, Europe, and Asia. Specialising in the manufacture of generic pharmaceuticals, Aurobindo Pharma offers a diverse portfolio that includes formulations, active pharmaceutical ingredients (APIs), and biosimilars. The company is recognised for its commitment to quality and innovation, which has propelled it to a leading position in the market. With numerous regulatory approvals and a robust pipeline of products, Aurobindo Pharma continues to achieve notable milestones, solidifying its reputation as a trusted provider of affordable healthcare solutions worldwide.
DitchCarbon Score
How does Aurobindo Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aurobindo Pharma's score of 16 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Aurobindo Pharma's reported carbon emissions
In 2023, Aurobindo Pharma reported total carbon emissions of approximately 941,472,000 kg CO2e, comprising 447,207,000 kg CO2e from Scope 1 and 494,264,000 kg CO2e from Scope 2 emissions. The company has shown a commitment to reducing its carbon footprint, with emissions decreasing from about 956,095,000 kg CO2e in 2020 to 858,885,000 kg CO2e in 2022, indicating a positive trend in their climate performance. Despite these reductions, Aurobindo Pharma has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company continues to monitor and report its emissions across all relevant scopes, including Scope 3 emissions, which were approximately 941,472,000 kg CO2e in 2023. Overall, Aurobindo Pharma's emissions data reflects a proactive approach to climate commitments, although further transparency regarding specific reduction targets would enhance their sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 409,572,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 523,611,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aurobindo Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
